Navigation Links
Data Presented at American Headache Society's Annual Scientific Meeting Show Primary Endpoint Met as Well as Improvement on Important Secondary Endpoints in Phase IIb Acute Migraine Trial of TorreyPines Therapeutics' Tezampanel
Date:6/30/2008

rrently developing four product candidates: two ionotropic glutamate receptor antagonists and two muscarinic receptor agonists. Further information is available at http://www.torreypinestherapeutics.com

This press release contains forward-looking statements or predictions. Such forward-looking statements include, but are not limited to, statements regarding the potential for tezampanel as a treatment for migraine and other forms of chronic pain such as neuropathic pain and fibromyalgia, as well as muscle spasticity and rigidity, thrombosis and epilepsy. Such statements are subject to numerous known and unknown risks, uncertainties and other factors, which may cause TorreyPines' actual results to be materially different from historical results or from any results expressed or implied by such forward- looking statements, including whether any preclinical studies or clinical trials conducted in the future, will prove successful, and if successful, whether the results can be replicated. These and other risks which may cause results to differ are described in greater detail in the "Risk Factors" section of TorreyPines' annual report on Form 10-K for the year ended December 31, 2007 and TorreyPines other SEC reports. The forward-looking statements are based on current information that is likely to change and speak only as of the date hereof.

Company Contact:

Paul Schneider

TorreyPines Therapeutics, Inc.

858-623-5665, x125

pschneider@torreypinestherapeutics.com

Media Contact:

David Schull

Russo Partners, LLC

212-845-4271

david.schull@russopartnersllc.com

Investor Contact:

Rhonda Chiger

Rx Communications

917-322-2569

rchiger@rxir.com


'/>"/>
SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Olanzapine Long-Acting Injection (LAI) Data Presented at First Annual Schizophrenia International Research Society Conference
2. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
3. Targeted Genetics Announces Positive Phase 1/2 tgAAC94 Data Presented at Annual European Congress of Rheumatology
4. After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008
5. Monotherapy BYETTA(R) (exenatide) Injection Study Results Presented at ADA 2008 Showed Adults with Type 2 Diabetes Experienced Improved Glycemic Control and Weight Loss
6. Interim Phase 1/2 Data of Ipilimumab in Prostate Cancer Presented at American Society of Clinical Oncology Annual Meeting
7. New Nexavar Data Presented in Multiple Tumor Types at 44th American Society of Clinical Oncology Annual Meeting
8. Preliminary Data from Ongoing Phase 1 Data of Investigational Anti-PD-1 Antibody Presented at American Society of Clinical Oncology Annual Meeting
9. Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments
10. New Analyses Presented at ASCO Reaffirmed Efficacy and Safety of TORISEL in Patients With Advanced Kidney Cancer
11. Data To Be Presented at ASCO Supports Potential of Peregrines Cotara(R) for the Treatment of Brain Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... Ore. , July 25, 2014  Semler ... an emerging medical risk assessment company that develops ... patients and evaluating chronic diseases, today reported financial ... ended June 30, 2014. "The ... for Semler," said Doug Murphy-Chutorian , M.D., ...
(Date:7/25/2014)... July 25, 2014 /PRNewswire-iReach/ -- Dr. Michael Gabriel ... Pediatrics, reacts to a recent study, which shows how grief ... - http://photos.prnewswire.com/prnh/20140723/129709 According to ... stress are more likely than others to grow up overweight ... There were two specific types of stress that ...
(Date:7/24/2014)... Wis. , July 24, 2014  Restore ... specialty and compounded pharmaceuticals, announced that it is ... information unique to each individual based upon their ... possible by understanding the interaction between a patient,s ... "We,re very excited to provide this new ...
Breaking Medicine Technology:Semler Reports Second Quarter 2014 Financial Results 2Semler Reports Second Quarter 2014 Financial Results 3Dr. Michael Gabriel of GPM Pediatrics, a Noted Staten Island Pediatrics Clinic, Comments on Study, Which Names Grief as a Cause of Obesity in Children 2Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 2Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 3
(Date:7/25/2014)... 25, 2014 Florida Hospital and MOSI officially ... organizations for years to come and make a difference in ... $2 million dollar check to provide the support needed to ... enable MOSI to transform the IMAX Dome Theatre from film ... the only IMAX Dome Theatre in the state of Florida, ...
(Date:7/25/2014)... human brain can preserve oxygen to protect itself from ... Although dehydration significantly reduces blood flow to the ... compensates by increasing the amount of oxygen it extracts ... understand a lot more about how the human brain ... author Steven Trangmar, a researcher at Brunel University, said ...
(Date:7/25/2014)... 2014 AttorneyOne.com, a recognized authority on law, ... the FDA on Ibuprofen and Oxcarbazepine Tablets . ... of Ibuprofen and one lot of Oxcarbazepine Tablets, by American ... packaging. Oxcarbazepine is used for the treatment of certain types ... reason for the recall is that Lot #142588, Expiration Date, ...
(Date:7/25/2014)... 25, 2014 A new study conducted by ... that 39 percent of all children in the survey under the ... survey looked at 2,505 children during the years of 2011 and ... of age. The final result was that about two out ... of these children were from lower-income families and were of East ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 A new study ... results of which are published today in Cancer , ... 55 and 74 who had an abnormal finding on a ... reduced quality of life than did those who were screened ... as a surprise to the researchers. “We expected that participants ...
Breaking Medicine News(10 mins):Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 2Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 3Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 4Health News:Human Brain Has Coping Mechanism for Dehydration 2Health News:Ibuprofen and Oxcarbazepine Tablets Recalled: AttorneyOne Monitors and Keep Consumers Informed 2Health News:North York Dental Provides Services to Toronto Children in Light of Growing Demand 2Health News:North York Dental Provides Services to Toronto Children in Light of Growing Demand 3Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 2Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 3Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 4Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 5
... in the Jan. 10 edition of the New England ... treatment and diagnosis of LAM, or lymphangioleiomyomatosis, a progressive ... childbearing years. There currently are no treatments for ... may be going misdiagnosed or undiagnosed. , Researchers ...
... Medicine professor of neurology, Peter Whitehouse, M.D., Ph.D., challenges ... new book, The Myth of Alzheimers: What You Arent ... provocative and ground-breaking new book, Dr. Whitehouse questions current ... brings a new understanding to everything we thought we ...
... The Quantum Group,Inc. (Amex: QGP, QGP.U) ... by Paulson Investment Company, a wholly owned subsidiary ... the lead underwriter for the,December 2007 public offering, ... will separate into its individual component parts; three,shares ...
... Inc. (AIM: TYR), the,pioneer of safer, effective ... achieved development and financial milestones from Arysta,LifeScience ... exclusive global,licensing and co-development agreement to manufacture ... certain horticultural markets., TyraTech is developing ...
... Jan. 10 With an eye to helping,customers ... ( http://www.bragada.com ) is now packing its Luxury ... features than before., All Bragada Luxury mattresses ... built into the fabric. One of the softest ...
... 9 The perception that,U.S. doctors are unwilling to ... untrue, according to a new study funded by HHS, ... doctors think that current systems to report and share,information ... with their colleagues. Consequently, important information,about medical errors and ...
Cached Medicine News:Health News:New research demonstrates potential diagnosis, treatment benefits 2Health News:New research demonstrates potential diagnosis, treatment benefits 3Health News:New research demonstrates potential diagnosis, treatment benefits 4Health News:International brain aging expert challenges the existence of Alzheimer's as a 'disease' 2Health News:International brain aging expert challenges the existence of Alzheimer's as a 'disease' 3Health News:The Quantum Group, Inc. Announces Separation of Units 2Health News:The Quantum Group, Inc. Announces Separation of Units 3Health News:TyraTech Achieves Insecticide Development and Financial Milestones With Partner Arysta LifeScience 2Health News:TyraTech Achieves Insecticide Development and Financial Milestones With Partner Arysta LifeScience 3Health News:Bragada(R) Luxury Mattress, Inc. Upgrades Luxury and Ultra Luxury Collections 2Health News:Physicians Want to Learn From Medical Mistakes But Say Current Error-Reporting Systems are Inadequate 2Health News:Physicians Want to Learn From Medical Mistakes But Say Current Error-Reporting Systems are Inadequate 3
Accommodates either eye. Slotted, malleable aluminum surface. Correct size holes produce ideal pin hole effect. Packaged 50 per box....
Blue plastic shield for reduced glare. Packaged 12 per box....
Non-reflective black anodized aluminum. Selection of five pin hole sizes (0.8 mm to 1.5 mm). Overall length: 4.0 inches....
4 mm x 4 mm downward biting jaws, curved right, length of shaft 115 mm, overall length 9.3 inches....
Medicine Products: